Prebiotic composition for butyrate-producing bacteria

By using alginic acid and/or its salts with a weight average molecular weight of less than 10,000 as prebiotics, the problem of butyric acid-producing bacteria in in vitro culture and application is solved, the growth of butyric acid-producing bacteria in the intestine is promoted, and it provides health-care Improved prebiotic compositions for use in food or medicine for intestinal regulation and other health uses.

CN114554874BActive Publication Date: 2024-12-06MORINAGA MILK IND CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080066803.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-09-27
Filing Date
2020-06-26
Publication Date
2024-12-06
Estimated Expiration
2040-06-26

AI Technical Summary

Technical Problem

The prior art is difficult to cultivate and formulate butyric acid bacteria in vitro, and its strong odor makes it unrealistic to use in food and drugs. The main butyric acid bacteria have high oxygen sensitivity and are difficult to survive in parenteral environments. and proliferation.

Method used

Alginic acid and/or its salt with a weight average molecular weight of less than 10,000 are used as prebiotics, and the molecular weight is reduced by hydrolyzing long-chain alginic acid and/or its salts, so that it can effectively promote the proliferation of Faepodium prazilian in the intestine and form Prebiotic compositions that assimilate and promote butyric acid-producing bacteria.

Benefits of technology

The proliferation of Faebacterium prazilian in the parenteral environment promotes the growth of butyric acid-producing bacteria in the intestines, provides prebiotic compositions that can improve health, for use in food or medicines, for use intestines. Uses such as tract regulation, immune regulation, reduced oxidative stress and prevention of diarrhea.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114554874B_ABST
    Figure CN114554874B_ABST
Patent Text Reader

Abstract

The object is to provide a prebiotic for the proliferation of butyrate-producing bacteria. A prebiotic composition for butyrate-producing bacteria, comprising alginic acid and / or a salt thereof having a weight average molecular weight of 10,000 or less.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a prebiotic composition for butyrate-producing bacteria. Background Art

[0002] In recent years, the correlation between intestinal bacteria and health has attracted attention and has been studied around the world. "Probiotics", a term known as a term related to improving the intestinal environment, generally refers to live microorganisms that bring beneficial effects to the human body by improving the balance of intestinal flora, and bifidobacteria and the like are generally known. In addition, as substances assimilated by the above-mentioned probiotics, there are "prebiotics", which are not decomposed / absorbed in the upper part of the digestive tract, but become a selective nutrient source for the beneficial bacteria symbiotically living in the large intestine, promote their proliferation, improve and maintain the composition of the intestinal flora in the large intestine, make it healthy and balanced, and help promote and maintain the health of the human body.

[0003] As one of the beneficial bacteria symbiotically living in the large intestine, there are butyrate-producing bacteria. Butyrate is a short-chain fatty acid present in the intestine. It is not only the main nutrient that provides energy to large intestinal cells, but also a cell mediator that regulates various functions including the intestinal tract, such as gene expression, cell differentiation, intestinal tissue development, immune regulation, oxidative stress reduction, and diarrhea control of the host (Non-Patent Document 1).

[0004] Although taking butyric acid into the body is beneficial to health, butyric acid releases a very strong and unpleasant odor, so it is not realistic to take it in the form of food, medicine, etc. In addition, the main butyric acid-producing bacteria living in the intestines are extremely oxygen-sensitive, so it is extremely difficult to culture them in vitro, and it is also difficult to prepare butyric acid-producing bacteria for ingestion (Non-Patent Document 2).

[0005] Prior art literature

[0006] Non-patent literature

[0007] Non-patent literature 1: Cell. 2016 Jun 2; 165(6): 1332-1345

[0008] Non-patent literature 2: Best. Pract. Res. Clin. Gastroenterol. 2017 Dec; 31(6): 643-648. Summary of the invention

[0009] Problem that the invention aims to solve

[0010] In view of the above situation, the present inventors have thought that it is useful to maintain / improve health by increasing the number of butyrate-producing bacteria living in the intestines. Therefore, an object of the present invention is to provide a prebiotic that increases the number of butyrate-producing bacteria, Faecalibacterium prausnitzii.

[0011] Solutions for solving problems

[0012] The present inventors conducted in-depth research to solve the above-mentioned problems and found that alginic acid and / or its salts can significantly proliferate butyrate-producing bacteria including Faecalibacterium prausnitzii in the intestine. Furthermore, the following insight was obtained: in a non-intestinal environment, that is, in the absence of bacteria other than butyrate-producing bacteria, Faecalibacterium prausnitzii cannot assimilate alginic acid and / or its salts having a certain size or more and will not proliferate. Based on this, it was thought that alginic acid and / or its salts of a specific size are effective as prebiotics for Faecalibacterium prausnitzii, and the present invention was completed.

[0013] That is, the first aspect of the present invention is a prebiotic composition for Faecalibacterium prausnitzii, comprising alginic acid and / or a salt thereof having a weight average molecular weight of 10,000 or less.

[0014] In the present embodiment, the butyrate-producing bacteria are preferably bacteria of the genus Faecalibacterium.

[0015] The composition of the present embodiment preferably contains 0.1% by mass or more of alginic acid and / or a salt thereof based on the entire composition.

[0016] The composition of this aspect is preferably a food or drink.

[0017] The composition of this embodiment is preferably a pharmaceutical product.

[0018] In addition, a second aspect of the present invention is a method for producing a prebiotic composition for butyrate-producing bacteria, comprising the step of hydrolyzing long-chain alginic acid and / or its salt to a weight average molecular weight of 10,000 or less.

[0019] In the present embodiment, the butyrate-producing bacteria are preferably bacteria of the genus Faecalibacterium.

[0020] In addition, the third embodiment of the present invention is a method for producing a prebiotic food and beverage for butyric acid bacteria, which includes the following steps: a step of hydrolyzing long-chain alginate and / or its salt to a weight average molecular weight of less than 10,000; and a step of adding alginate and / or its salt having a weight average molecular weight of less than 10,000 obtained in the aforementioned step to the food and beverage raw materials.

[0021] In the present embodiment, the butyrate-producing bacteria are preferably bacteria of the genus Faecalibacterium.

[0022] Effects of the Invention

[0023] According to the present invention, a prebiotic capable of efficiently increasing Faecalibacterium prausnitzii can be provided. Since butyric acid produced by Faecalibacterium prausnitzii functions as a cell medium and maintains and improves health, the present invention is very useful industrially. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1This is an HPLC chart comparing the molecular weights of sodium alginate (sample 1) and an external standard (pullulan).

[0025] Figure 2 It is a graph showing the time-dependent change in the turbidity of a culture medium when Faecalibacterium prausnitzii was cultured in a culture medium to which sodium alginate (sample 1 (●), sample 2 (○)) or guar gum hydrolyzate (sample 3 (△)) with different molecular weights was added, or in a culture medium to which no sample was added (◇).

[0026] Figure 3 These are HPLC chromatograms of the culture medium and a pullulan standard substance when Faecalibacterium prausnitzii was cultured alone in a culture medium supplemented with sodium alginate (sample 1) and after culturing for 0 or 48 hours.

[0027] Figure 4 These are HPLC charts of the culture medium and sample 1 after 0 or 48 hours of cultivation when Faecalibacterium prausnitzii was cultured alone in a culture medium supplemented with sodium alginate (sample 1). DETAILED DESCRIPTION

[0028] Next, the present invention will be described in detail. However, the present invention is not limited to the following embodiments, and can be freely modified within the scope of the present invention.

[0029] The composition of the present invention contains alginic acid and / or its salt (hereinafter also referred to as "alginic acid") having a weight average molecular weight of 10,000 or less. The upper limit of the weight average molecular weight is preferably 9,000 or less, more preferably 8,000 or less, further preferably 7,000 or less, and particularly preferably 5,000 or less. The lower limit of the weight average molecular weight is not particularly limited, and is usually 194 or more. Here, the weight average molecular weight of alginate is the value when converted to alginic acid.

[0030] The composition of the present invention may contain alginic acid and / or a salt thereof having a weight average molecular weight larger than the above numerical range, unless the effect thereof is impaired.

[0031] The weight average molecular weight of alginic acid in this specification is a value measured by HPLC method under the following conditions.

[0032] Measuring machine: Ultimate 3000 (manufactured by Thermo Corporation)

[0033] Detection: Refracto Max 521 detector (manufactured by Thermo Corporation),

[0034] Column: TSKgel G3000PW (manufactured by Tosoh Corporation)

[0035] Mobile phase: 0.1M sodium nitrate aqueous solution

[0036] Flow rate: 0.3mL / min

[0037] Column temperature: 40°C

[0038] Standard product: STANDARD P-82 (manufactured by Shodex)

[0039] It should be noted that the molecular weight measured by HPLC under the above conditions is an "apparent" value that may deviate from the actual "real" molecular weight calculated from the degree of polymerization.

[0040] As shown in the examples described below, the molecular weight of alginate oligosaccharides having a degree of polymerization of 4 to 5 is about 3,500 when measured under the above conditions.

[0041] Therefore, the alginic acid contained in the composition of the present invention may be an oligosaccharide having a degree of polymerization of preferably 20 or less, more preferably 10 or less, further preferably 8 or less, and particularly preferably 5 or less.

[0042] The molecular weight of the alginic acid contained in the composition of the present invention when measured by HPLC method under the following conditions can be lower than 40,000. In addition, its upper limit is preferably less than 35,000, more preferably less than 30,000, more preferably less than 25,000, and particularly preferably less than 22,000. In addition, the lower limit of the molecular weight when measured by HPLC method under the following conditions is not particularly limited, usually more than 194, more preferably more than 5,000, more preferably more than 10,000. Here, the molecular weight of alginate is the value when converted to alginic acid.

[0043] The conditions here are as follows.

[0044] Measuring machine: Ultimate 3000 (manufactured by Thermo Corporation)

[0045] Detection: Corona charged particle detector (manufactured by Thermo),

[0046] Column: TSKgel G6000PW (manufactured by Tosoh Corporation)

[0047] Mobile phase: 0.1% ammonium acetate in water

[0048] Flow rate: 0.4 mL / min

[0049] Column temperature: 40°C

[0050] Standard product: STANDARD P-82 (manufactured by Shodex)

[0051] It should be noted that the molecular weight measured by HPLC under the above conditions may also deviate from the "apparent" value of the "real" molecular weight calculated from the actual degree of polymerization.

[0052] Alginic acid is a polysaccharide contained in seaweed such as kelp and wakame, and is widely used, including in food as a thickening stabilizer. Alginic acid has a straight chain structure consisting of β-D-mannuronic acid and α-L-guluronic acid connected by 1-4 bonds. The degree of polymerization of alginic acid varies depending on its source.

[0053] Examples of the salt of alginic acid include sodium salt, potassium salt, calcium salt, and ammonium salt. Although not particularly limited in the present invention, sodium salt and potassium salt are preferred from the viewpoint of water solubility.

[0054] Generally, alginic acid can be extracted from seaweed, etc., and commercial products are also available. Their molecular weight is usually as high as about 40,000 to several million. According to the experiments of the present inventors, it was confirmed that Faecalibacterium prausnitzii alone cannot assimilate these "long-chain alginic acids" with a weight average molecular weight exceeding 10,000.

[0055] The alginic acid with a weight average molecular weight of 10,000 or less used as an effective ingredient of the prebiotic composition of the present invention can be obtained by hydrolyzing the "long-chain alginic acid". That is, as another embodiment of the present invention, a method for producing a prebiotic composition for Faecalibacterium prausnitzii can be provided, the method comprising the step of hydrolyzing the long-chain alginic acid and / or its salt to a weight average molecular weight of 10,000 or less.

[0056] Examples of the hydrolysis method include an acid hydrolysis method, a method using a hydrolase, and a method using bacteria having a hydrolase.

[0057] Specifically, the acid hydrolysis is performed by adding a weak acid such as acetic acid to an aqueous solution of the long-chain alginic acid and heating the solution to a high temperature, for example, 100° C. or higher, for several hours, but the present invention is not limited thereto.

[0058] As the hydrolase, for example, a commercially available hydrolase is allowed to act on the long-chain alginic acid to perform hydrolysis.

[0059] Examples of bacteria having a hydrolase include commercially available bacteria of the genus Flavobacterium, and these bacteria can be hydrolyzed by culturing them in the presence of long-chain alginic acids under appropriate conditions.

[0060] The amount of the alginic acid of the weight average molecular weight below 10000 in the composition of the present invention can be suitably set according to the form of the composition, is not particularly limited, for example, preferably more than 0.1 mass % of the overall composition, more preferably more than 1 mass % is advisable. The upper limit of the content of the alginic acid of the weight average molecular weight below 10000 is not particularly limited, for example, can be less than 5 mass % of the overall composition, or can be less than 100 mass %. It should be noted that, in the case of alginate, these numerical values ​​are values ​​converted to alginic acid. In addition, these contents include the value when manufacturing the composition of the present invention, the value when circulating, and the value when taking in (giving).

[0061] The composition of the present invention can be used as a prebiotic for butyrate-producing bacteria, that is, it can be assimilated by butyrate-producing bacteria and promote their proliferation.

[0062] It should be noted that butyric acid-producing bacteria is a general term for bacteria that produce butyric acid. The butyric acid-producing bacteria in the present invention are not particularly limited, and examples thereof include Faecalibacterium, and more specifically, Faecalibacterium prausnitzii existing in the human intestine.

[0063] The composition of the present invention is useful for diseases or conditions that can be prevented or improved by increasing butyric acid in the body, or for subjects suffering from diseases or conditions caused by a decrease in butyric acid in the body. For example, the composition can be used for intestinal regulation, immunomodulation, oxidative stress reduction, or prevention / improvement of diarrhea, inflammatory bowel disease, and prevention of colorectal cancer.

[0064] Another embodiment of the present invention is use of alginic acid and / or a salt thereof having a weight average molecular weight of 10,000 or less in the production of a prebiotic composition for butyrate-producing bacteria.

[0065] Another aspect of the present invention is use of alginic acid and / or a salt thereof having a weight average molecular weight of 10,000 or less for proliferation of Faecalibacterium prausnitzii.

[0066] Another aspect of the present invention is alginic acid and / or a salt thereof having a weight average molecular weight of 10,000 or less for proliferation of Faecalibacterium prausnitzii.

[0067] A method for proliferating Faecalibacterium prausnitzii, comprising administering alginic acid and / or a salt thereof having a weight average molecular weight of 10000 or less to an animal. Here, the animal is not particularly limited, and is usually a human.

[0068] The timing of ingestion (administration) of the composition of the present invention is not particularly limited and can be appropriately selected according to the state of the subject to be administered.

[0069] The intake (administration) amount of the composition of the present invention can be appropriately selected according to the age, sex, state, other conditions, etc. of the object of intake (administration). As the amount of alginic acid with a weight average molecular weight of 10,000 or less, it is preferably based on 1 to 300 mg / kg / day, more preferably 20 to 50 mg / kg / day.

[0070] In addition, regardless of the amount and period of ingestion (administration), the drug may be administered once a day or in divided doses.

[0071] The ingestion (administration) route of the composition of the present invention may be either oral or parenteral, but is usually oral. In addition, examples of parenteral ingestion (administration) include rectal administration and the like.

[0072] The composition of the present invention may also be in a form containing butyrate-producing bacteria together with alginic acid having a weight average molecular weight of 10,000 or less. In addition, the composition of the present invention may also be used in combination with butyrate-producing bacteria or a preparation containing butyrate-producing bacteria for ingestion. By the above manner, the effect of promoting the proliferation of butyrate-producing bacteria in the intestine and the butyrate-increasing effect brought about by the effect can be further expected.

[0073] In addition, in the case of these aspects, the butyrate-producing bacteria are preferably live bacteria.

[0074] When the composition of the present invention is made into a composition to be orally ingested, it is preferably made into a form of food or drink.

[0075] As a food or beverage, as long as it can be orally ingested without impairing the effects of the present invention, there is no particular limitation on the form and properties, and it can be produced using raw materials commonly used in food or beverages and by a common method, except that it contains alginic acid with a weight average molecular weight of 10,000 or less.

[0076] As mentioned above, generally, the alginics generally available are long-chain, and therefore, a prebiotic food and beverage for butyrate-producing bacteria can also be manufactured by a method comprising the following steps as another embodiment of the present invention, the steps being: a step of hydrolyzing long-chain alginic acid and / or its salt to a weight-average molecular weight of less than 10,000; and a step of adding alginate and / or its salt having a weight-average molecular weight of less than 10,000 obtained in the aforementioned step to the food and beverage raw materials.

[0077] As food and beverages, there are no restrictions on the form of liquid, paste, gelatinous solid, powder, etc., and examples thereof include compressed sugar; liquid food (nutritious food for ingestion by tube); wheat flour products such as bread, macaroni, spaghetti, noodles, cake mixes, fried flour, bread crumbs, etc.; instant noodles, cup noodles, steamed / cooked food, canned food, microwave food, instant soup / Japanese stew, instant miso soup / inhalation, canned soup, freeze-dried / dried food, other instant foods, etc.; canned crops, canned fruits, jam (jam) / marmalade (Marmalade); processed agricultural products such as canned fish, fish ham / sausage, aquatic minced food, aquatic fish and shellfish, and tsukudani; processed livestock products such as canned livestock / paste, ham / sausage; processed milk, milk drinks, yogurt, lactic acid bacteria drinks, cheese, ice cream, formula milk powder, cream, and other dairy products; butter, margarine, vegetable oil and other fats and oils; soy sauce, miso, sauce (Sauce), tomato seasoning, flavor Basic seasonings such as vinegar and edible vinegar; cooking mixes, curry ingredients, fish sauces, dressings, noodle soups, spices, other compound seasonings and other compound seasonings / foods; frozen food ingredients, semi-cooked frozen foods, cooked frozen foods and other frozen foods; caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese snacks, rice cakes Snacks such as heart-shaped and bean snacks, Western desserts, jellies, and other snacks; snacks such as carbonated drinks, natural fruit juices, fruit juice drinks, refreshing drinks with fruit juice, pulp drinks, fruit drinks with fruit pulp, vegetable drinks, soy milk, soy milk drinks, coffee drinks, tea drinks, powdered drinks, concentrated drinks, sports drinks, nutritional drinks, alcoholic drinks, and other snack drinks; other commercially available foods such as baby food, rice companion, tea rice and kelp, etc.; formula milk powder for raising children; enteral nutritional foods; functional foods (specific health foods, nutritional functional foods), etc.

[0078] In addition, as one form of food and drink, feed may be used. Examples of feed include pet food, livestock feed, and fish feed.

[0079] There are no particular restrictions on the form of the feed. In addition to alginates with a weight-average molecular weight of less than 10,000, the feed may contain, for example, alginates with a weight-average molecular weight greater than 194, cereals such as corn, wheat, barley, rye, and West African sorghum; vegetable oil meals such as soybean oil meal, rapeseed oil meal, coconut oil meal, and linseed oil meal; brans such as bran, wheat bran, rice bran, and defatted rice bran; manufactured meals such as corn gluten meal and corn paste; animal feeds such as fish meal, skimmed milk powder, whey, feed oils and fats, and beef tallow; yeasts such as round yeast and brewer's yeast; mineral feeds such as tricalcium phosphate and calcium carbonate; oils and fats; monomeric amino acids; sugars, etc.

[0080] When the composition of the present invention is in the form of a food or beverage (including feed), it can be provided / sold as a food or beverage with a label indicating that it is a prebiotic for butyrate-producing bacteria or that it is used to increase butyrate-producing bacteria in the intestine.

[0081] The above-mentioned "labeling" behavior includes all behaviors used to make the person in need aware of the above-mentioned use. As long as it is a label that can remind or infer the above-mentioned use, regardless of the labeling purpose, labeling content, labeling object / medium, etc., it is equivalent to the "labeling" of the present invention.

[0082] In addition, the "marking" is preferably marked in a manner that allows the user to directly recognize the above-mentioned use. Specifically, the following may be cited: the act of transferring, delivering, displaying, or importing items with the above-mentioned use recorded on the food and beverage products or the packaging of the products; the act of recording the above-mentioned use in advertisements, price lists, or transaction documents related to the products and displaying or publishing the above-mentioned use; or the act of recording the above-mentioned use in information with these as the content and providing it through electromagnetic methods (such as the Internet).

[0083] On the other hand, the labeling content is preferably a labeling that is authorized by the administration or the like (for example, a labeling that is authorized based on various systems stipulated by the administration and is performed in a form based on such authorization). In addition, such labeling content is preferably displayed on packaging, containers, product catalogs, brochures, POP and other sales promotion materials, and other documents.

[0084] In addition, "labeling" can also be exemplified by labels such as health food, functional food, enteral nutrition food, special purpose food, health function food, specific health food, nutrition function food, functional label food, quasi-drug, etc. Among them, in particular, labels approved by the Consumer Affairs Agency, such as specific health food, nutrition function food, or functional label food related systems, or labels approved by similar systems, etc. Specifically, it can be listed as a label as a specific health food, a label as a specific health food as an additional condition, a label that aims to affect the structure and function of the body, a label that reduces the risk of disease, a functional label based on scientific evidence, etc. More specifically, a typical example is the label of a specific health food (especially a label for health use) determined by the Cabinet Office Order (Cabinet Office Order No. 57 of August 31, 2011) on the approval of special purpose labels stipulated in the Health Promotion Act, etc., and similar labels.

[0085] Examples of the above-mentioned indication include “those who wish to increase butyrate-producing bacteria in the abdomen”, “those who wish to increase Faecalibacterium bacteria”, and “intestinal regulation effect with butyrate”.

[0086] The composition of the present invention can be prepared in the form of a medicine.

[0087] The administration route of the drug is preferably oral or parenteral, and oral is preferred. In addition, examples of parenteral ingestion (administration) include rectal administration and the like.

[0088] As the form of the drug, it can be prepared into a suitable desired dosage form according to the administration method. For example, in the case of oral administration, it can be prepared into solid preparations such as powders, granules, tablets, capsules, etc.; liquid preparations such as solution preparations, syrups, suspensions, emulsions, etc. In addition, in the case of parenteral administration, it can be prepared into suppositories, ointments, injections, etc.

[0089] When preparing, except the alginic acid class with weight average molecular weight below 10000, can use the components such as excipient, pH adjusting agent, coloring agent, flavoring agent that are usually used for preparing.In addition, also can use in combination other medicinal ingredients, known or prebiotics that will be found in the future etc.

[0090] In addition, the preparation can be carried out by using a known method as appropriate according to the dosage form. When preparing the preparation, a preparation carrier can be appropriately mixed for preparation.

[0091] Examples of the excipient include: sugar derivatives such as lactose, saccharose, glucose, mannitol, and sorbitol; starch derivatives such as corn starch, potato starch, α-starch, dextrin, and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, and carboxymethyl cellulose calcium; gum arabic; dextran; pullulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminosilicate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; sulfate derivatives such as calcium sulfate, etc.

[0092] Examples of the binder include gelatin, polyvinyl pyrrolidone, and macrogol in addition to the above-mentioned excipients.

[0093] Examples of the disintegrant include, in addition to the above-mentioned excipients, chemically modified starches or cellulose derivatives such as cross-linked sodium carboxymethylcellulose, sodium carboxymethyl starch, and cross-linked polyvinyl pyrrolidone.

[0094] Examples of lubricants include talc, stearic acid, metal stearates such as calcium stearate and magnesium stearate, silica gel, waxes such as colloidal magnesium aluminum silicate (VEEGUM) and spermaceti, boric acid, glycol, carboxylic acids such as fumaric acid and adipic acid, sodium carboxylate sodium salts such as sodium benzoate, sulfates such as sodium sulfate, leucine, lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate, silicic acids such as silicic anhydride and silicic acid hydrate, starch derivatives, and the like.

[0095] Examples of the stabilizer include p-hydroxybenzoic acid esters such as methyl p-hydroxybenzoate and propyl p-hydroxybenzoate; alcohols such as chlorobutanol, benzyl alcohol, and phenethyl alcohol; benzalkonium chloride; acetic anhydride; and sorbic acid.

[0096] Examples of the flavoring and smelling agents include sweeteners, sour agents, and flavoring agents.

[0097] Examples of carriers used in liquid preparations for oral administration include solvents such as water.

[0098] The timing of taking the drug of the present invention is not particularly limited, for example, before meals, after meals, during meals, before bedtime, etc.

[0099] Example

[0100] The present invention will be described in more detail below using examples, but the present invention is not limited to these examples.

[0101] <Manufacturing example>

[0102] (1) Obtaining long-chain sodium alginate hydrolysate

[0103] 1 g of commercially available sodium alginate raw material ("ULV-L3 (molecular weight 40,000-60,000)" (manufactured by KIMICA Corporation)) was dissolved in 99.7 mL of MilliQ water. Then, 0.3 mL of acetic acid (Kochika Co., Ltd.) was added and autoclaved at 104°C for 7.5 hours. Then, centrifugation was performed at 8000×g for 5 minutes to recover the supernatant. The supernatant was subjected to rapid reflux (speed back) and all acetic acid and 70% of water were removed to obtain an aqueous solution of a hydrolyzate of long-chain sodium alginate (sample 1).

[0104] (2) Estimation of the molecular weight of sodium alginate

[0105] The molecular weight of the sodium alginate (sample 1) obtained in (1) was determined by HPLC. Sample 1 was passed through a 0.22 μm filter (manufactured by Merck Millipore) and subjected to HPLC.

[0106] HPLC used Ultimate3000 (manufactured by Thermo), Corona charged particle detector (manufactured by Thermo), and TSKgel G6000PW (manufactured by Tosoh Corporation). P-82 pullulan standard (manufactured by Shoudex Corporation) was used as external standard. The mobile phase was distilled water dissolved with 0.1% ammonium acetate and the measurement was performed isocratically for 110 minutes. The flow rate was set to 0.4 mL / min and the column oven temperature was set to 40°C.

[0107] Figure 1 The HPLC spectra of sample 1 and external standard are shown. The Mp (peak molecular weight) of P-5 is 6600, the Mp of P-20 is 23000, and the Mp of P-50 is 48800. It is estimated that the Mp of sample 1 based on the above measurement conditions is less than 40000.

[0108] <Test Example 1> Single culture of Faecalibacterium prausnitzii 1

[0109] (1) Preparation of culture medium

[0110] To the sodium alginate aqueous solution (sample 1) obtained in the above-mentioned Production Example was added a powder of the YCFA medium composition excluding sugar to obtain a YCFA medium containing sodium alginate.

[0111] As a comparison, a culture medium containing a commercially available sodium alginate raw material or a guar gum hydrolyzate was prepared. It should be noted that guar gum hydrolyzate is known to have the ability to proliferate Faecalibacterium prausnitzii. First, 0.3 mL of acetic acid (Kokusho Chemical Co., Ltd.) was added to 99.7 mL of MilliQ water, and an autoclave treatment was applied at 104°C for 7.5 hours. The obtained sterilized water was subjected to rapid reflux, and 70% of all acetic acid and water were removed to obtain an aqueous solution. 1 g of a commercially available sodium alginate raw material (sample 2: "ULV-L3 (molecular weight 40,000 to 60,000)" (manufactured by KIMICA Corporation) or a commercially available guar gum hydrolyzate (sample 3: "Sunfiber" (manufactured by Sun Chemical Co., Ltd.)) was added to the aqueous solution, and then a YCFA culture medium composition powder other than sugar was added to obtain a YCFA culture medium. In addition, as a negative control, a culture medium without the addition of the sample to be tested was also prepared.

[0112] (2) Solo culture

[0113] To each YCFA medium prepared in (1), a vitamin solution and a cysteine ​​solution sterilized by a filter were added in an aseptic manner to prepare a culture solution with a final concentration of 1% (w / v) of the test sample. The culture solution was injected into a 96-well plate 353072 (manufactured by Falcon) at a volume of 200 μL each. Then, the 96-well plate was left to stand overnight in Concept Plus (manufactured by Central Chemical Company) to replace the culture solution with an anaerobic state. Faecalibacterium prausnitzii (MCC2041, internationally deposited on September 20, 2019 at the National Institute for Technology Evaluation, Patent Microorganism Collection Center (Postal Number 292-0818, Room 122, 2-5-8, Kazusa Kamata, Kisarazu-shi, Chiba Prefecture) under the deposit number NITE BP-03027) was inoculated therein 24 hours before the culture experiment and anaerobically cultured at 37°C, 6 μL of the pre-culture solution thus obtained was inoculated into the culture solution, and anaerobically cultured at 37°C for 48 hours.

[0114] Figure 2 The turbidity (OD 600 ). Faecalibacterium prausnitzii could not assimilate sodium alginate (sample 2) with a large molecular weight and proliferated slowly, but sodium alginate (sample 1) whose molecular weight was reduced by hydrolysis was assimilated and significant proliferation was observed. In addition, compared with guar gum hydrolyzate (sample 3), sample 1 showed a higher proliferation ability of Faecalibacterium prausnitzii.

[0115] <Test Example 2> Single culture of Faecalibacterium prausnitzii 2

[0116] Faecalibacterium prausnitzii (MCC2041, deposit number: NITE BP-03027) was cultured alone using the YCFA medium supplemented with Sample 1 prepared in the same manner as in Test Example 1. The culture medium was collected 0 hours and 48 hours after the start of the culture, and HPLC was performed.

[0117] HPLC used Ultimate3000 (manufactured by Thermo), Corona charged particle detector (manufactured by Thermo), and TSKgel G3000PW (manufactured by Tosoh Corporation). P-82 pullulan standard (manufactured by Shoudex Corporation) was used as an external standard. The mobile phase was distilled water dissolved with 0.1% ammonium acetate and the measurement was performed isocratically for 110 minutes. The flow rate was set to 0.3 mL / min and the column oven temperature was set to 40°C.

[0118] Figure 3 The spectra of each culture medium and the standard product after 0 hour and 48 hours from the start of culture are overlapped. Before and after the culture, the molecular weight range of about 25,000 to 10,000 decreases, especially the peak of about 20,000 decreases, so it can be seen that alginic acid with a molecular weight in this range is assimilated by Faecalibacterium prausnitzii. It should be noted that the decrease in the spectrum around 27 minutes is considered to be equivalent to the consumption of culture medium-derived components.

[0119] <Test Example 3> Single culture of Faecalibacterium prausnitzii

[0120] Faecalibacterium prausnitzii (MCC2041, deposit number: NITE BP-03027) was cultured alone using the YCFA medium supplemented with Sample 1 prepared in the same manner as in Test Example 1. The culture medium was collected 0 hours and 48 hours after the start of the culture, and HPLC was performed.

[0121] HPLC used Ultimate3000 (manufactured by Thermo), Refracto Max 521 (manufactured by Thermo), and TSKgel G3000PW (manufactured by Tosoh Corporation). P-82 pullulan standard (manufactured by Shoudex) was used as an external standard. The mobile phase was distilled water dissolved with 0.1% sodium nitrate and the measurement was performed isocratically for 80 minutes. The flow rate was set to 0.3 mL / min and the column oven temperature was 40°C.

[0122] Figure 4 The spectra of each culture medium and sample 1 are superimposed 0 hour and 48 hours after the start of culture. Before and after the culture, the peak around 31 to 32.5 minutes from the start of the measurement decreased, and the peak was roughly consistent with the peak that appeared in sample 1, so it was found that alginic acid with a molecular weight in this range was assimilated by Faecalibacterium prausnitzii.

[0123] Figure 4 The weight average molecular weight of the fraction corresponding to the peak that decreased before and after the culture, i.e., alginic acid assimilated by Faecalibacterium prausnitzii, was calculated based on the standard curve prepared from the elution time of the external standard, and was estimated to be about 3500. In addition, the weight average molecular weight of sample 1 was calculated, and was estimated to be about 6000.

[0124] <Test Example 4> Analysis of Faecalibacterium prausnitzii assimilated fraction

[0125] The size of the alginic acid assimilated by F. prausnitzii was analyzed in more detail by thin layer chromatography (TLC).

[0126] The culture solution of Test Example 3 after 48 hours of culture and the YCFA medium added with Sample 1 prepared in the same manner as in Test Example 1 were centrifuged at 13000×g and 4°C for 3 minutes, and each supernatant was recovered as a sample. As standard products, Sample 1, commercially available long-chain sodium alginate ("ULV-L3 (molecular weight 40,000 to 60,000)" (manufactured by KIMICA Corporation)), commercially available alginate oligosaccharides (mainly containing 2 to 6 sugars. "Alginate oligosaccharides (AOS)" (manufactured by Hokkaido Mitsui Chemicals Co., Ltd.)), glucose, maltose, and raffinose were prepared.

[0127] 1 μL of each sample was spotted on an aluminum plate for thin layer chromatography, silica gel 60 (Merck), and developed with a developing solvent (formic acid: 1-butanol: distilled water = 6:4:1). After spraying with a diphenylamine·aniline·phosphoric acid reagent (100 mL acetone, 1 g diphenylamine, 1 mL aniline, 10 mL phosphoric acid), the sample was heated to color the sugar.

[0128] In sample 1, which is a hydrolyzate of long-chain sodium alginate, multiple spots were observed. The spots are roughly the same as the multiple spots that appear in alginate oligosaccharides, so it can be inferred that sample 1 is oligosaccharides obtained by decomposing long-chain sodium alginate into 2-6 sugars. It should be noted that the above spots did not appear in long-chain sodium alginate.

[0129] In addition, in the culture solution, spots corresponding to oligosaccharides, particularly tetrasaccharides and pentasaccharides, respectively, in Sample 1 were observed to be lighter than before culture. This indicates that Faecalibacterium prausnitzii assimilated sugars with several degrees of polymerization, particularly tetrasaccharides and pentasaccharides, in the hydrolyzate of long-chain alginic acid.

Claims

1. Use of alginic acid and / or its salt having a weight average molecular weight of less than 10,000 in the manufacture of a prebiotic composition for butyrate-producing bacteria, wherein: The butyrate-producing bacteria is a bacterium of the genus Faecalibacterium, and the bacterium of the genus Faecalibacterium is Faecalibacterium prausnitzii.

2. The use according to claim 1, wherein: The composition contains 0.1 mass % or more of alginic acid and / or a salt thereof based on the entire composition.

3. The use according to claim 1, wherein: The composition is a food or drink.

4. The use according to claim 1, wherein: The composition is a medicine.